证券代码：600201 证券简称：生物股份 编号：临2024-045 金宇生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 相关股东是否存在减持计划：公司董事、监事、高级管理人员、持股 5%以 上股东内蒙古金宇生物控股有限公司(以下简称"生物控股")及其一致行动人未 来 3 个月、未来 6 个月不存在减持计划。如上述主体未来拟实施股份减持计划，公 司将遵守中国证监会和上海证券交易所关于股份减持的相关规定，及时履行信息披 露义务。 相关风险提示 1、本次回购股份期限内，若公司股票价格持续超出回购方案披露的回购价格 上限，存在回购方案无法顺利实施的风险； 2、若发生对公司股票交易价格产生重大影响的重大事项, 或公司生产经营、 财务状况、外部客观情况发生重大变化，可能存在公司董事会根据相关规则决定终 止本次回购方案的风险； 3、本次回购的股份将用于员工持股计划或股权激励, 可能存在因相关方案未 能经公司董事会和股东大会审议通过、激励对象放弃认购等原因 ...

金宇生物技术股份有限公司(以下简称"公司")第十一届监事会第十五次会 议通知于 2024 年 10 月 15 日以电子邮件、书面形式发出，会议于 2024 年 10 月 30 日下午 15:00 在公司会议室以现场和通讯表决相结合的方式召开，应出席监事 3 人，实际出席监事 3 人。会议的召集、召开程序符合《公司法》及《公司章程》 的规定。会议由监事会主席董人美女士主持，审议并通过了如下议案： 审议并通过《公司 2024 年第三季度报告》 证券代码：600201 证券简称：生物股份 公告编号：临 2024-044 金宇生物技术股份有限公司 第十一届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：3 票同意、0 票反对、0 票弃权。 公司监事会对董事会编制的 2024 年第三季度报告进行了审核，并发表意见如 下： 1、公司 2024 年第三季度报告编制和审议程序符合法律、法规、《公司章程》 和公司内部管理制度的各项规定； 2、公司 2024 年第三季度报告的内容和格式符合中国证监会和上海证券 ...

各位投资者朋友下午好欢迎大家参加生物股份2024年半年度业绩说明会本次业绩说明会出席的公司领导有董事长张冲宇先生非独立董事副董事长兼总裁张静女士非独立董事财务总监兼董事会秘书彭敏先生独立董事张桂红女士本次说明会我们分为两个部分 第一部分为生物股份2024年半年度报告解读第二部分我们就投资者关系的问题进行文字互动回答首先我们将通过视频解读公司报告主要从公司概况经营情况战略规划及落地三个方面进行解读首先是公司概况 第一 发展历程三十年以来生物股份始终以坚韧不拔的意志开拓创新的精神以及前瞻性的战略定位紧跟时代步伐推动行业发展集团发展历程中几个重要的时间节点上市 经理生物鱼1993年成立是内蒙古自治区首批股份制试点企业1998年 公司股票在上海证券交易所上市 并购,2007年并购扬州邮邦,2017年收购苗林易康丰富了公司动物疫苗产品管线2019年与日本公立合作成立合资公司进军宠物药品疫苗领域 口第一发展2009年国内首条口第一疫苗悬浮纯化生产线投产引领产业升级2011年开创口第一疫苗市场化营销新模式精语生物成为行业龙头企业建立实验室公司2008年荣获受用疫苗国家工程实验室资质2017年荣英农业部返出动物生物制品重点实 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2024-042 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 09 月 27 日(星期五) 下午 15:00-16:30 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2024 年 09 月 20 日(星期五) 至 09 月 26 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stock@jinyu.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 金宇生物技术股份有限公司（以下简称"公司"）已于 2024 年 8 月 31 日披 露公司《2024 年半年度报告》，为便于广大投资者更全面深入地了解公司 2024 年上半年的经营成果、财务状况，公司计划于 2024 年 09 ...

Investment Rating - Strong Buy/Maintain [2] Core Views - The company reported H1 2024 revenue of 612 million yuan, a yoy decrease of 10.66%, and net profit attributable to shareholders of 123 million yuan, a yoy decrease of 8.56% [2] - Despite the challenging environment in the pig farming industry, the company's ruminant vaccines showed strong growth, with multiple new products such as high-end brucellosis vaccines and sheep vaccines being launched [2] - The company's gross profit margin in H1 2024 was 57.92%, up 0.31 percentage points yoy, and the net profit margin was 20.21%, up 0.89 percentage points yoy [2] - The company is expected to see a recovery in pig vaccines in H2 2024 as farming profitability improves [2] - The company is actively advancing R&D, with 75 million yuan invested in H1 2024, accounting for 12.26% of revenue, and several new vaccines in the registration stage [2] - The company is building the world's first animal mRNA vaccine production facility, expected to be operational by 2025, and has established an AI + synthetic biology innovation platform [2] Financial Forecasts - The company is expected to achieve net profit attributable to shareholders of 328 million yuan, 418 million yuan, and 524 million yuan in 2024, 2025, and 2026, respectively [2] - EPS is forecasted to be 0.29 yuan, 0.37 yuan, and 0.47 yuan for 2024, 2025, and 2026, respectively [2] - The PE ratio is expected to be 20x, 16x, and 13x for 2024, 2025, and 2026, respectively [2] Industry and Market Data - The company is a leading player in the animal health industry, with a product portfolio covering over 100 vaccines for pigs, poultry, pets, and ruminants [4] - The company has production qualifications for foot-and-mouth disease and highly pathogenic avian influenza vaccines, with leading domestic technology and product quality [4] - The company's 52-week stock price range is 10.87 yuan to 5.96 yuan, with a total market capitalization of 6.677 billion yuan [4] Financial Metrics - Revenue is expected to grow from 1.732 billion yuan in 2024 to 2.490 billion yuan in 2026, with a CAGR of 19.54% [5] - Net profit attributable to shareholders is expected to grow from 328 million yuan in 2024 to 524 million yuan in 2026, with a CAGR of 25.46% [5] - ROE is forecasted to increase from 5.88% in 2024 to 8.46% in 2026 [5] - Gross margin is expected to remain stable at around 60% from 2024 to 2026 [5]

金宇生物技术股份有限公司 关于股东股份质押展期及补充质押的公告 证券代码：600201 证券简称：生物股份 公告编号：临 2024-041 | 内蒙古金 宇生物控 | 否 | 14,110,000 | 否 | 否 | 2023 | 年 | 9 | 2024 | 年 | 9 | 2024 | 年 | 12 | 中信建投 证券股份 | 11.54 | 1.26 | 融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股有限公 | | | | | 月 | 5 | 日 | 月 | 4 日 | | 月 | 4 日 | | 有限公司 | | | 周转 | | 司 | | | | | | | | | | | | | | | | | | | 内蒙古金 宇生物控 | 否 | 3,500,000 | 否 | 否 | 2024 | 年 | 8 | 2024 | 年 | 9 | 2024 | 年 | 12 | 中信建投 证券股份 | 2.86 | 0.3 ...

2024 年 09 月 04 日 公司研究 评级：买入(维持) | --- | --- | |--------------|---------------------------------------------| | | | | 研究所： | | | 证券分析师： | 程一胜 S0350521070001 chengys01@ghzq.com.cn | | 证券分析师： | 熊子兴 S0350522100002 xiongzx@ghzq.com.cn | [Table_Title] 盈利能力稳中有升，产品研发进入收获期 ——生物股份（600201）2024 年半年报点评 最近一年走势 事件: 2024 年 8 月 30 日，生物股份发布 2024 年半年报：2024H1 公司实现营 业收入 6.12 亿元，同比-10.66%，归母净利润 1.23 亿元，同比-8.56%， 扣非归母净利润 1.08 亿元，同比-12.56%。2024Q2，公司实现营业收入 2.64 亿元，同比-17.74%，归母净利润 0.17 亿元，同比-37.47%，扣非 归母净利润 0.13 亿元，同比-44.69%。 投资要点: ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 611,731,208.51, a decrease of 10.66% compared to CNY 684,715,029.34 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was CNY 122,918,629.44, down 8.56% from CNY 134,425,016.21 in the previous year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 107,863,778.98, a decrease of 12.56% compared to CNY 123,351,878.62 in the same period last year[13]. - The net cash flow from operating activities was CNY 130,730,764.81, down 7.05% from CNY 140,647,025.50 in the previous year[13]. - Basic earnings per share for the reporting period (January to June) decreased to CNY 0.11, down 8.33% from CNY 0.12 in the same period last year[14]. - Diluted earnings per share also fell to CNY 0.11, reflecting an 8.33% decrease compared to the previous year[14]. - The weighted average return on equity decreased to 2.28%, down 0.34 percentage points from 2.62% year-on-year[14]. - The company reported a net profit of CNY 140,242,688.08 for the first half of 2024, compared to CNY 150,852,361.09 in the same period of 2023, a decrease of 7.06%[78]. - The total comprehensive income for the first half of 2024 was CNY 127,355,974.12, slightly lower than CNY 132,472,865.35 in the first half of 2023, reflecting a decrease of around 4%[80]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,931,063,807.55, an increase of 0.85% from CNY 6,872,581,837.59 at the end of the previous year[13]. - The net assets attributable to shareholders of the listed company were CNY 5,388,723,021.43, an increase of 0.41% from CNY 5,366,883,193.66 at the end of the previous year[13]. - The company's total liabilities increased from CNY 1,217,642,217.42 to CNY 1,420,269,397.62, representing an increase of approximately 16.6%[74]. - The company's total assets increased from CNY 6,872,581,837.59 to CNY 6,931,063,807.55, a growth of about 0.9%[74]. - The total equity attributable to the parent company at the end of the first half of 2024 is CNY 5,366,883,193.66, a decrease of CNY 144,145,210.24 compared to the previous period[89]. - The company's total liabilities at the end of the first half of 2024 are CNY 1,500,000,000.00, indicating a stable financial position[90]. Research and Development - R&D investment amounted to 75 million RMB, representing 12.26% of operating revenue[25]. - The company established an integrated R&D platform for African swine fever vaccines, making significant breakthroughs in subunit and mRNA vaccine development[25]. - The company has established multiple R&D platforms supported by national engineering laboratories and key laboratories, enhancing its innovation capabilities and efficiency in vaccine development[21]. - The company emphasizes the importance of continuous product innovation and quality control in the increasingly competitive veterinary biological products industry[35]. - The company has a strong emphasis on collaboration with research institutions and universities to leverage theoretical and data advantages in its R&D efforts[21]. Market Position and Strategy - The company operates in the veterinary medicine manufacturing industry, which has seen market growth from CNY 41.213 billion in 2013 to CNY 67.345 billion in 2022[16]. - The company plans to enhance its production technology and expand its market presence in response to the growing demand for veterinary products[16]. - The company aims to enhance its market position by continuously innovating and expanding its vaccine portfolio to address emerging animal health challenges[21]. - The company has implemented a differentiated marketing strategy through comprehensive disease prevention solutions, enhancing market share of key products and expanding into high-potential markets[22]. - The company is focused on expanding its product offerings through capital-driven initiatives and new business models[21]. Environmental and Compliance - The company has established a dedicated EHS department to enforce environmental management systems and ensure compliance with pollution control measures[55]. - The company actively responded to national environmental protection requirements, establishing management systems and emergency plans, with no environmental accidents reported[54]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[52]. - The company has completed the environmental protection acceptance for its projects, including solid waste pollution prevention facilities[47]. - The company has received environmental impact assessment approvals for multiple projects since 2014, ensuring compliance with regulations[47]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 55,040[67]. - The largest shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., holds 122,304,000 shares, accounting for 10.92% of the total shares[68]. - The second largest shareholder, Weixing Asset Management (Shanghai) Co., Ltd., increased its holdings by 8,462,900 shares to a total of 40,769,355 shares, representing 3.64%[68]. - The company reported no changes in the total number of shares or share capital structure during the reporting period[66]. - There were no significant related party transactions or major contracts reported during the period[65]. Financial Management and Accounting Policies - The financial statements are prepared based on the going concern principle and comply with the relevant accounting standards[98]. - The company has implemented specific accounting policies for fixed asset depreciation and revenue recognition tailored to its operational characteristics[100]. - The company recognizes expected credit losses for financial instruments in different stages, with provisions based on the entire expected lifetime for those that have experienced credit impairment[129]. - The company assesses expected credit losses based on the weighted average of credit losses for financial instruments, considering past events, current conditions, and forecasts of future economic conditions[128]. - The company recognizes revenue when control of goods or services is transferred to the customer, with specific methods for different types of sales, including real estate and property services[173].

证券代码：600201 证券简称：生物股份 公告编号：临 2024-039 金宇生物技术股份有限公司 关于股东股份补充质押的公告 公司于 2024 年 8 月 22 日接到持股 5%以上股东生物控股函告，获悉其将所持 有 3,500,000 股无限售流通股股票质押给中信建投证券股份有限公司，作为对前 期股份质押的补充质押，具体事项如下： | 占其 | 占公 | 是否 | 质押 | 是否 | 所持 | 司总 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 为控 | 本次质押股 | 是否为 | 质押 | 质押 | 融资 | 补充 | 质权人 | 股份 | 股本 | 名称 | 股股 | 数（股） | 限售股 | 起始日 | 到期日 | 资金 | | 质押 | 比例 | 比例 | 东 | 用途 | （%） | （%） | | | | | | | | | | | | 1、本次股份质押基本情 ...

证券代码: 600201 证券简称:生物股份 金宇生物技术股份有限公司 关于参加内蒙古辖区 2024 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，金宇生物技术股份有限公司（以下简 称"公司"）将参加由内蒙古证监局、内蒙古自治区上市公司协会与深圳市全景 网络有限公司联合举办的"内蒙古辖区上市公司 2024 年投资者网上集体接待日 活动"，现将相关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 (http://rs.p5w.net）,或关注微信公众号:全景财经,或下载全景路演 APP, 参与本次互动交流,活动时间为 2024年 8 月 9 日（周五） 15:00-17:00。届时 公司高管将在线就公司 2023 年度业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流，欢迎广大投资者踊跃参与！ 特此公告。 金宇生物技术股份有限公司 董 事 会 二〇二四年八月六日 ...